col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


30 Results       Page 1

 [1] 
Elsevier: Biochemical Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2026―Apr―25 4-Octyl itaconate blocks STAT3-induced ACE2 expression to reduce uptake of SARS-CoV-2 Hauke J. Weiss, Alexander Hooftman, Clarisse Salgado-Benvindo, Robbert Boudewijns, Laurens Liesenborghs, Tristram A.J. Ryan, et al. (+9)
2 [GO] 2026―Feb―17 From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2 Xin Zhang, Yuxin Xu, Yunzhi Jiang, Junjie Huang, Xiaolin Li
3 [GO] 2025―Jan―17 Corrigendum to “Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin” [Biochem. Pharmacol. 215 (2023) 115688] Cheng-Wei Yang, Hsing-Yu Hsu, Yue-Zhi Lee, Jia-Tsrong Jan, Sui-Yuan Chang, Yi-Ling Lin, et al. (+10)
4 [GO] 2024―Jun―22 Takotsubo syndrome as an outcome of the use of checkpoint inhibitor therapy in patients with COVID-19 Júlia Leão Batista Simões, Geórgia de Carvalho Braga, João Victor Coiado, Alexandre Bachietti Scaramussa, Ana Paula Barasuol Rodrigues, Margarete Dulce Bagatini
5 [GO] 2024―Feb―17 Developing CAR-immune cell therapy against SARS-COV-2: Current status, challenges, and prospects Yizhao Chen, Chong Liu, Yilong Fang, Weile Chen, Jiaqi Qiu, Mengjuan Zhu, et al. (+2)
6 [GO] 2023―Dec―09 Bile acids and bile acid activated receptors in the treatment of Covid-19 Stefano Fiorucci, Ginevra Urbani, Michele Biagioli, Valentina Sepe, Eleonora Distrutti, Angela Zampella
7 [GO] 2023―Jul―21 Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin Cheng-Wei Yang, Hsing-Yu Hsu, Yue-Zhi Lee, Jia-Tsrong Jan, Sui-Yuan Chang, Yi-Ling Lin, et al. (+10)
8 [GO] 2023―Jan―30 Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators Nusrath Yasmeen, S. Harikrishnan, Sudarshan S Lakhawat, Manali Datta, Pushpender K Sharma, Ajay Jain, et al. (+3)
9 [GO] 2022―Dec―30 Applications of Nanobodies in the Prevention, Detection, and Treatment of the Evolving SARS-CoV-2 Wenyi Wang, Yue Hu, Bohan Li, Huanan Wang, Jinhua Shen
10 [GO] 2022―Dec―05 Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic Hongyin Chen, Jiangyun Peng, Tengyao Wang, Jielu Wen, Sifan Chen, Yu Huang, Yang Zhang
11 [GO] 2022―Oct―31 Glycosylation in SARS-CoV-2 Variants: A path to Infection and Recovery Arya Aloor, Rajaguru Aradhya, Parvathy Venugopal, Bipin Gopalakrishnan Nair, Renuka Suravajhala
12 [GO] 2022―Oct―06 An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges Xiaoying Xu, Yuheng Chen, Xinyu Lu, Wanlin Zhang, Wenxiu Fang, Luping Yuan, Xiaoyan Wang
13 [GO] 2022―Jul―03 JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 Jin Huang, Chi Zhou, Jinniu Deng, Jianfeng Zhou
14 [GO] 2021―Nov―18 The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders Upasana Parthasarathy, Roberta Martinelli, Elisabeth H. Vollmann, Katharine Best, Alex G. Therien
15 [GO] 2021―Aug―08 Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) Yusen Xiang, Mengge Wang, Hongzhuan Chen, Lili Chen
16 [GO] 2021―Apr―02 Animal Models for SARS-Cov2/Covid19 Research-A Commentary Kurt Jarnagin, Oscar Alvarez, Sujan Shresta, David R Webb
17 [GO] 2021―Feb―10 Sleep during COVID-19 lockdown: A cross-cultural study investigating job system relevance Cristina Florea, Pavlos Topalidis, Theresa Hauser, Monika Angerer, Anton Kurapov, Carlos Alberto Beltran Leon, et al. (+2)
18 [GO] 2021―Jan―28 PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking Claire Lugnier, Hayder M. AL-Kuraishi, Eric Rousseau
19 [GO] 2021―Jan―19 Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics Li Zeng, Dongying Li, Weida Tong, Tieliu Shi, Baitang Ning
20 [GO] 2020―Oct―27 The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro Junke Song, Li Zhang, Yanfeng Xu, Dezhi Yang, Li Zhang, Shiying Yang, et al. (+13)
21 [GO] 2020―Oct―22 Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, Nikhilesh Alahari, Suresh K. Alahari
22 [GO] 2020―Oct―04 Corrigendum to “Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost” [Biochem. Pharmacol. 178 (2020) 114057] Manar Mohammed El Tabaa, Maram Mohammed El Tabaa
23 [GO] 2020―Sep―20 AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication Jonathan O. Rayner, Rosemary A. Roberts, Jin Kim, Andrew Poklepovic, Jane L. Roberts, Laurence Booth, Paul Dent
24 [GO] 2020―Sep―19 Role of Proteolytic Enzymes In the Covid-19 Infection And Promising Therapeutic Approaches Magda Gioia, Chiara Ciaccio, Paolo calligari, Giovanna De Simone, Diego sbardella, Grazia tundo, et al. (+6)
25 [GO] 2020―Sep―06 The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations Meik Neufurth, Xiaohong Wang, Emad Tolba, Ingo Lieberwirth, Shunfeng Wang, Heinz C. Schröder, Werner E.G. Müller
26 [GO] 2020―Jul―30 COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials Rohan Chakraborty, Suhel Parvez
27 [GO] 2020―Jul―23 Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2 Lucia Lisi, Pedro Miguel Lacal, Maria Luisa Barbaccia, Grazia Graziani
28 [GO] 2020―Jun―25 Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction Gary Williamson, Asimina Kerimi
29 [GO] 2020―Jun―21 SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management Lin Wu, Aislinn M. O'Kane, Hu Peng, Yaguang Bi, Dagmara Motriuk-Smith, Jun Ren
30 [GO] 2020―May―27 Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost Manar Mohammed El Tabaa, Maram Mohammed El Tabaa
 [1] 

30 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec